Renalytix (RNLX) Stock

Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX”

Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage

Renalytix Plc (NASDAQ:RNLX) will be hosting a conference call on May 15, 2024 at 8:30 AM ET to discuss the company's Q3 2024 financial results. Company representatives Peter DeNardo, James McCullough, James Sterling, and Howard Doran will be participating in the call. Analysts Dan Arias, Randy Baron, Mark Massaro, and Jens Lindqvist will also be in attendance. The operator will provide instructions for the call. Good morning, and thank you for joining the Renalytix conference call for the review of Third Quarter Fiscal Year 2024 Financial Results.

Renalytix dropped by more than a third as its latest interim results show more big losses and a shrinking cash pile. Losses are inevitable for an early-stage company such as Renalytix, which is developing diagnostics tools for kidney illness sufferers, but the scale seemingly is raising some alarms.

Shares in Renalytix PLC (AIM:RENX) jumped almost 30% on Friday after the diagnostics firm revealed a draft Medicare determination for its kidney function tests. The Centers for Medicare and Medicaid Services published the draft local coverage determination on Thursday, Renalytix said, relating to the use of its tests for those on the US state-funded medical insurance programme.

Renalytix AI PLC Sponsored ADR (RNLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Renalytix PLC (AIM:RENX) shares fell 12% to 46.09p after it said newly allowed US patents further strengthen the core intellectual property underpinning its KidneyIntelX blood test technology. The US Patent Office issued a new notice of allowance of claims surrounding the biomarkers sTNFR1 and sTNFR2 used in the kidneyintelX.dkd test.

Renalytix AI PLC Sponsored ADR (RNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Shares of Renalytix PLC (AIM:RENX) surged 28% in early trading after the Centers for Medicare & Medicaid Services (CMS) announced a price of $950 for the company's FDA-approved kidneyintelX.dkd test. The test, which uses artificial intelligence to predict risks for people with type 2 diabetes and chronic kidney disease, will be listed on the nationwide Clinical Laboratory Fee Schedule starting January 1, and the price will be locked in for at least three years.